Why clinical trials exist and who they are for

Clinical trials answer a specific medical question. Some test new drugs, biologics, devices, or digital tools; others compare standard-of-care approaches. A trial’s design determines who it is meant to help, what outcomes are measured, and how safety is tracked. In the U.S., studies generally follow Good Clinical Practice (GCP), require independent ethics review by an Institutional Review Board (IRB), and use a formal informed consent process to make sure participation is voluntary and informed.

Trials are not only for people with serious illnesses. Many studies enroll healthy adults (for example, in vaccine or pharmacology research) or people with risk factors who do not yet have a diagnosis. Whether a trial is appropriate depends on your health status, the protocol’s inclusion and exclusion criteria, and your willingness to follow visit schedules.

Where to search (and how to use the tools)

ClinicalTrials.gov is the official U.S. registry and results database. It contains basic information about registered trials, including eligibility, status (for example, “Recruiting”), locations, and a study contact. To use it efficiently:

1. Start with a plain-language condition or keyword. Examples: “asthma,” “migraine,” “knee osteoarthritis,” “type 2 diabetes,” “healthy adult.”
2. Filter to live opportunities. Use “Recruiting,” “Enrolling by invitation,” and “Not yet recruiting” if you’re early and want to be notified.
3. Set a location radius. Enter your ZIP and choose a distance that fits your travel limits (for instance, 25–50 miles).
4. Open the study record. Read “Brief Summary,” “Eligibility Criteria,” and “Contacts and Locations.” Pay attention to whether you meet all the inclusion criteria and none of the exclusions.
5. Check the study’s control/comparator setup. Some trials have a placebo or active-comparator arm. The consent form will explain randomization (how assignment works).

If you prefer phone guidance, many academic medical centers have research navigation services that help patients understand clinical research and search public registries. These services are informational; they don’t “get you into” a study—eligibility still depends on the protocol.

Understanding a study listing: what matters most

Each record summarizes key details. The most important fields to review are:

• Condition or focus: Verify that your diagnosis (or healthy status) matches the trial’s intended population.
• Phase: Early-phase studies (e.g., Phase 1) prioritize safety and dosing in smaller groups; later phases (2/3) focus on effectiveness and side effects in larger populations. Post-approval studies (Phase 4) look at long-term outcomes or subgroups.
• Interventions: What is being tested (drug, device, procedure, behavioral, digital app)? Will you need to stop certain medications?
• Eligibility criteria: Inclusion criteria define who can join; exclusion criteria protect safety or scientific validity (for example, specific lab values or recent procedures).
• Recruitment status and sites: “Recruiting” indicates active enrollment. Confirm there is a site within your travel range.
• Contacts: There should be a named contact or site coordinator. Listings without real contacts are a red flag.

Listings vary in depth. If something isn’t clear, write down your questions and ask the study team directly during pre-screen or screening.

Eligibility in practice: inclusion, exclusion, and screening

Most trials begin with a pre-screen—a short call or form that checks basics (age, diagnosis, medications, distance to site). If you appear to qualify, the site schedules a screening visit. This formal visit typically includes reviewing the consent document, medical history, physical exams, and lab tests specific to the protocol. You are not “in the study” until you satisfy all eligibility checks and the research team confirms enrollment.

Eligibility is not personal. If you don’t qualify, it’s usually because the protocol requires a narrow definition to ensure results answer the research question safely. You can ask whether the site or sponsor knows of similar trials for which you might qualify.

Informed consent: what you will read and discuss

Before any study procedure, you will receive an informed consent form (paper or electronic). The consent explains the study’s purpose, procedures, risks and discomforts, potential benefits (if any), alternatives, privacy protections (including HIPAA where applicable), compensation or reimbursements, injury language, emergency contacts, and the voluntary nature of participation. An IRB reviews this document to help protect participants’ rights and welfare.

You should have time to read and ask questions. Consent is not a test—clarifying questions are welcomed. You may take the document home, talk with family, and return later. Signing does not obligate you to complete the study; you can withdraw at any time without penalty or loss of benefits you would otherwise have.

Time, travel, and compensation: realistic expectations

Study participation often includes multiple visits with set procedures (for example, questionnaires, vitals, blood draws, imaging, device usage, or app-based diaries). Many trials reimburse travel/parking and may provide a stipend for time and inconvenience. Amounts and methods vary by protocol. Ask whether payments are per-visit or lump-sum, how missed visits are treated, and whether receipts are required for reimbursements.

Compensation does not remove risk and should not pressure you to join. If you are unsure about any aspect of payment, ask the coordinator to show you the exact language in the consent document and explain it in plain terms.

Safety first: verifying legitimacy and spotting red flags

A legitimate U.S. study will have a public record you can verify and a real clinical site. Use this quick approach:

1. Ask for the NCT number. Every registered study on ClinicalTrials.gov has an NCT identifier. Look up the record and confirm that the sponsor, purpose, and contacts match.
2. Check the site location. Legitimate sites are clinics, hospitals, or research centers with addresses you can verify publicly.
3. Look for proper process. You should be given time to read consent, ask questions, and decide. High-pressure tactics and requests for upfront payment are red flags.

If something feels wrong, you can walk away. It’s your decision.

What happens after you express interest

1. Pre-screen: a short call or web form to check high-level criteria and logistics.
2. Consent discussion and screening: a longer appointment to review the consent document, collect medical history, and perform protocol-specific tests.
3. Enrollment decision: if you meet all criteria and still wish to participate, the team schedules your first study visit.
4. Study visits: you complete procedures described in the protocol. You can always ask for a break or clarification.
5. End of study and follow-up: you may have follow-up visits or calls. You may ask how and when results will be shared publicly.

Participants vs professionals: why some pages seem technical

ClinicalTrials.gov serves multiple audiences: participants, clinicians, and researchers. If terminology is confusing, ask the coordinator to explain terms in plain language. You can also search for plain-English summaries on public, non-commercial sources (for example, medical school sites that host patient education pages). If you still cannot interpret a listing, note your questions and bring them to your call with the research team.

Key terms you’ll see (plain English)

IRB (Institutional Review Board)

An independent committee that reviews research to help protect participant rights and welfare.

GCP (Good Clinical Practice)

International quality standard for designing, conducting, recording, and reporting clinical research.

AE / SAE (Adverse Event / Serious Adverse Event)

Medical problems that occur during a study; serious events require rapid attention and reporting.

Randomization

A chance-based method of assigning participants to different groups (for example, treatment vs placebo) to reduce bias.

Placebo

An inactive substance or procedure used to compare against the investigational intervention.

Where to learn more (official resources)

• ClinicalTrials.gov — U.S. trial registry & results
• FDA: Clinical Trials — What Patients Need to Know
• OHRP (HHS): Participant FAQs

FAQs